Salsali, Afshin

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

Voors, A. A., Angermann, C. E., Teerlink, J. R., Collins, S. P., Kosiborod, M., Biegus, J., Ferreira, J. P., Nassif, M. E., Psotka, M. A., Tromp, J., et al. (2022) · Nature Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 951

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME ® trial

Fitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2016) · European Heart Journal

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 907

Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension

Tikkanen, I., Narko, K., Zeller, C., Green, A., Salsali, A., Broedl, U. C., & Woerle, H. J. (2015) · Diabetes Care

Blood Pressure and Hypertension StudiesDiabetes Treatment and Management

Cited by 468

Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes

Abraham, W. T., Lindenfeld, J., Ponikowski, P., Agostoni, P., Butler, J., Desai, A. S., Filippatos, G., Gniot, J., Fu, M., Gullestad, L., et al. (2021) · European Heart Journal

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 217

Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial

Fitchett, D., Inzucchi, S. E., Zinman, B., Wanner, C., Schumacher, M., Schmoor, C., Ohneberg, K., Ofstad, A. P., Salsali, A., George, J. T., et al. (2021) · ESC Heart Failure

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 85